Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Sea Changes In Regulation And The Market: Top Stories Of 2008

This article was originally published in The Tan Sheet

Executive Summary

When an iconic drug brand drew scrutiny on Capitol Hill for possibly violating FDA's policy against combinations of drugs and dietary supplements, OTC and supplement interests took notice

You may also be interested in...

P&G Focuses On Consumer Health, “Deemphasizes” Pharma

Procter & Gamble says consumer health trends are on its side as the company increases focus on its consumer health business and moves away from pharmaceuticals

P&G Says Zegerid Switch Proposal Should Drop “Immediate Release” Claim

The proton pump inhibitor Zegerid should not be allowed on the over-the-counter market with the label claim "immediate release," says Prilosec OTC marketer Procter & Gamble

The JUPITER Results: Will The Planets Align For OTC Statins?

AstraZeneca's JUPITER trial onCrestor (rosuvastatin) greatly expands the pool of patients who may benefit from statin use, which could help make the case for an OTC switch in the cholesterol-lowering class in the future

Related Content





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts